Redacted Southern Hemisphere Flu JA 2025 2026.pdf

This is a Justification for Other than Full and Open Competition document for the procurement of Southern Hemisphere Influenza Vaccine by the Defense Logistics Agency (DLA) Troop Support, Medical Supply Chain. The document justifies a one-year firm fixed price indefinite quantity contract with Sanofi Pasteur Inc., who is identified as the sole FDA-approved manufacturer of the Southern Hemisphere Flu vaccine in the US.

The contract requirements specify a minimum quantity of 4,500 packages (45,000 doses) and a maximum of 9,000 packages (90,000 doses), with NSN 6505-01-722-0304. A Sources Sought Notice was posted on SAM.gov from July 2 to August 2, 2024, receiving only two responses - one from Sanofi Pasteur and another from BHPE LLC, though BHPE LLC's response did not provide the requested information. The vaccine (Fluzone® Southern Hemisphere) is for active immunization against influenza virus in persons six months and older, specifically targeting the Southern Hemisphere influenza season which runs from April through October. The contract was awarded as SPE2DP25D0001, with approval signatures dated October 7, 2024.